What is the primary reason for this amended 10-K filing?

This filing is an Amendment No. 1 to the annual report to address comments received from the SEC related to a registration statement and to provide expanded and clarified disclosures on various business and financial matters.

What are the key financial trends highlighted in this filing?

Bristol-Myers Squibb reported a significant year-over-year increase in earnings from continuing operations in 2003, largely due to robust sales growth from key products like PRAVACHOL and PLAVIX and the absence of major charges seen in the prior year. However, the company anticipates substantial revenue declines in the coming years due to patent expiries on several major products.

What significant risks does the company face regarding its product portfolio?

The company faces significant 'exclusivity losses' as patents expire on major products, leading to anticipated substantial reductions in sales. For example, the company estimates $1.2 to $1.3 billion in sales reductions in 2004 alone and projects similar losses in the following years. The success of offseting these losses relies on the performance of its in-line products, recently launched drugs, pipeline candidates, and is subject to outcomes of patent litigations, particularly for PLAVIX.

Are there any ongoing legal or regulatory issues that investors should be aware of?

Yes, the company is subject to ongoing investigations by the SEC and the U.S. Attorney's Office concerning wholesaler inventory and other accounting issues, for which it has reserved $150 million. It also faces significant litigation related to major products like PLAVIX patent challenges, as well as product liability and pricing/marketing practices lawsuits.

BRISTOL MYERS SQUIBB CO 10-K FY2003 Annual Report

Summary

Bristol-Myers Squibb Company (BMY) filed this 10-K/A filing on June 27, 2004, to amend its annual report for the year ended December 31, 2003. The amendment was made in response to comments from the SEC regarding a registration statement. It includes expanded disclosures on clinical trial results for PRAVACHOL, termination provisions of strategic alliances, remedial actions for disclosure controls, a restatement adjustment for goods-in-transit, clarification on revenue recognition, and details on an asset write-down. The filing also provides an update on recent significant corporate events, including patent litigation, a class action lawsuit dismissal, earnings announcements, and an increase in legal reserves. Key financial data reflects a significant increase in earnings from continuing operations before minority interest and income taxes, up 70% year-over-year, driven by sales growth and the absence of large charges incurred in the prior year. However, the company faces significant revenue challenges due to upcoming patent expiries on key products, estimating sales reductions of $1.2 to $1.3 billion in 2004 alone, with further losses projected in subsequent years. Management believes growth in other key products and pipeline products will offset these losses, though this is contingent on patent litigation outcomes and regulatory approvals.

Key Highlights

1The company is filing an amendment (10-K/A) to its 2003 annual report to address SEC comments and include expanded disclosures on various operational and financial matters.

2Significant product lines like PRAVACHOL and PLAVIX showed strong sales growth in 2003, with PRAVACHOL reaching $2.8 billion and PLAVIX $2.5 billion.

3Earnings from continuing operations before minority interest and income taxes increased substantially by 70% in 2003 due to increased sales and fewer one-time charges compared to 2002.

4The company faces significant 'exclusivity losses' from patent expiries, estimating $1.2-$1.3 billion in sales reductions for 2004 and projecting further losses of $1-$1.3 billion annually in 2005-2007.

5The company is actively managing its pipeline with key late-stage products expected to contribute significantly by 2007, aiming to offset revenue declines from expiring patents.

6The company incurred substantial litigation and restructuring charges in prior years, but these were largely absent in 2003, contributing to the earnings improvement.

7The company is subject to ongoing investigations by the SEC and U.S. Attorney's Office concerning wholesaler inventory issues and other accounting matters, and has reserved $150 million related to these.

8Significant strategic alliances are in place for key products like PLAVIX (with Sanofi), ABILIFY (with Otsuka), and ERBITUX (with ImClone).

BRISTOL MYERS SQUIBB CO Annual Report (Amendment), Year Ended Dec 31, 2003

Summary

Key Highlights

Frequently Asked Questions